Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
NBIX

NBIX - Neurocrine Biosciences Inc Stock Price, Fair Value and News

145.82USD+1.68 (+1.17%)Market Closed

Market Summary

NBIX
USD145.82+1.68
Market Closed
1.17%

NBIX Alerts

  • 5 major insider sales recently.

NBIX Stock Price

View Fullscreen

NBIX RSI Chart

NBIX Valuation

Market Cap

14.7B

Price/Earnings (Trailing)

39.69

Price/Sales (Trailing)

7.4

EV/EBITDA

28.93

Price/Free Cashflow

23.88

NBIX Price/Sales (Trailing)

NBIX Profitability

Operating Margin

99.28%

EBT Margin

23.71%

Return on Equity

15.49%

Return on Assets

10.65%

Free Cashflow Yield

4.19%

NBIX Fundamentals

NBIX Revenue

Revenue (TTM)

2.0B

Rev. Growth (Yr)

22.57%

Rev. Growth (Qtr)

0.02%

NBIX Earnings

Earnings (TTM)

369.7M

Earnings Growth (Yr)

156.66%

Earnings Growth (Qtr)

-70.62%

Breaking Down NBIX Revenue

Last 7 days

-1.1%

Last 30 days

11.4%

Last 90 days

10.5%

Trailing 12 Months

48.9%

How does NBIX drawdown profile look like?

NBIX Financial Health

Current Ratio

2.52

Debt/Equity

0.07

Debt/Cashflow

3.81

NBIX Investor Care

Shares Dilution (1Y)

3.14%

Diluted EPS (TTM)

3.67

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20242.0B000
20231.6B1.7B1.8B1.9B
20221.2B1.3B1.4B1.5B
20211.0B1.0B1.1B1.1B
2020886.8M1.0B1.0B1.0B
2019518.6M605.1M675.5M788.1M
2018232.7M323.3M414.3M451.2M
201706.3M67.1M161.6M
201615.0M15.0M15.0M15.0M
201522.0M21.2M20.5M19.8M
201340.6M28.0M15.5M2.9M
201276.2M74.6M42.3M53.1M
201145.3M52.8M80.0M77.4M
2010013.1M23.3M33.5M
20090003.0M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Neurocrine Biosciences Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jul 16, 2024
lippoldt darin
acquired
553,456
79.02
7,004
chief legal officer
Jul 16, 2024
delaet ingrid
sold
-428,627
150
-2,857
chief regulatory officer
Jul 16, 2024
lyons gary a
acquired
39,766
42.76
930
-
Jul 16, 2024
abernethy matt
acquired
66,240
73.6
900
chief financial officer
Jul 16, 2024
lyons gary a
sold
-139,530
150
-930
-
Jul 16, 2024
delaet ingrid
acquired
202,589
103
1,957
chief regulatory officer
Jul 16, 2024
cooke julie
acquired
55,638
61.82
900
chief human resources officer
Jul 16, 2024
lippoldt darin
sold
-1,050,590
149
-7,004
chief legal officer
Jul 16, 2024
cooke julie
sold
-135,036
150
-900
chief human resources officer
Jul 16, 2024
abernethy matt
sold
-135,037
150
-900
chief financial officer

1–10 of 50

Which funds bought or sold NBIX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 19, 2024
NISA INVESTMENT ADVISORS, LLC
reduced
-2.88
-30,439
964,654
0.01%
Jul 19, 2024
Continuum Advisory, LLC
unchanged
-
-46.00
3,166
-%
Jul 19, 2024
RAYMOND JAMES & ASSOCIATES
reduced
-0.75
-77,590
8,245,600
-%
Jul 19, 2024
Chesley Taft & Associates LLC
sold off
-100
-1,034,400
-
-%
Jul 19, 2024
First Pacific Financial
sold off
-100
-4,690
-
-%
Jul 19, 2024
Hennion & Walsh Asset Management, Inc.
reduced
-0.84
-9,549
928,997
0.05%
Jul 19, 2024
HARBOR INVESTMENT ADVISORY, LLC
sold off
-100
-1,517
-
-%
Jul 19, 2024
Raymond James Financial Services Advisors, Inc.
new
-
318,431
318,431
-%
Jul 19, 2024
First Horizon Advisors, Inc.
added
6.27
6,550
114,403
-%
Jul 19, 2024
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A.
unchanged
-
-14,856
8,181,040
1.33%

1–10 of 50

Are Funds Buying or Selling NBIX?

Are funds buying NBIX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own NBIX
No. of Funds

Unveiling Neurocrine Biosciences Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
9.88%
9,710,328
SC 13G/A
Jan 23, 2024
blackrock inc.
13.9%
13,647,679
SC 13G/A
Feb 09, 2023
janus henderson group plc
2.5%
2,415,638
SC 13G/A
Feb 09, 2023
vanguard group inc
9.72%
9,340,295
SC 13G/A
Jan 23, 2023
blackrock inc.
13.1%
12,627,403
SC 13G/A
Feb 14, 2022
price t rowe associates inc /md/
4.5%
4,359,645
SC 13G/A
Feb 10, 2022
vanguard group inc
9.26%
8,787,991
SC 13G/A
Feb 10, 2022
janus henderson group plc
7.8%
7,445,839
SC 13G/A
Jan 27, 2022
blackrock inc.
12.1%
11,476,545
SC 13G/A
Jan 26, 2022
blackrock inc.
12.1%
11,476,545
SC 13G/A

Recent SEC filings of Neurocrine Biosciences Inc

View All Filings
Date Filed Form Type Document
Jul 18, 2024
4
Insider Trading
Jul 18, 2024
4
Insider Trading
Jul 18, 2024
4
Insider Trading
Jul 18, 2024
4
Insider Trading
Jul 18, 2024
4
Insider Trading
Jul 16, 2024
144
Notice of Insider Sale Intent
Jul 16, 2024
144
Notice of Insider Sale Intent
Jul 16, 2024
144
Notice of Insider Sale Intent
Jul 16, 2024
144
Notice of Insider Sale Intent
Jul 16, 2024
144
Notice of Insider Sale Intent

Peers (Alternatives to Neurocrine Biosciences Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
372.4B
85.6B
6.23% -8.11%
9.68
4.35
5.68% 202.39%
318.7B
61.4B
-1.70% 16.00%
138.18
5.19
6.11% -82.30%
177.7B
29.5B
8.27% 42.04%
47.23
6.02
12.76% -52.47%
169.7B
35.0B
9.27% -18.55%
146.05
4.84
-26.40% -92.03%
90.4B
27.4B
14.93% -9.21%
186.63
3.29
1.51% -91.32%
18.9B
16.0B
-1.18% 98.47%
-38.18
1.18
7.23% 71.10%
MID-CAP
4.2B
1.7B
1.72% -22.30%
9.68
2.44
54.01% 364.56%
3.8B
4.6B
9.59% -20.45%
-495.71
0.84
-0.06% 94.55%
2.8B
9.0B
17.62% -20.65%
-6.13
0.31
10.01% -27.45%
1.9B
676.2M
-1.12% -37.39%
12.52
2.86
30.38% 66.04%
SMALL-CAP
1.4B
743.2M
5.33% 7.88%
-3.91
1.85
24.65% 80.36%
21.2M
1.3M
-1.08% -55.56%
-2.86
16.12
-98.14% -104.71%
14.8M
89.6M
11.54% -18.69%
-1.04
0.19
287.27% -129.41%
9.8M
21.5M
320.59% -52.65%
-1.26
0.46
66.16% 61.84%
322.9K
115.7M
-61.54% -97.23%
0
0
-2.22% -352.48%

Neurocrine Biosciences Inc News

Latest updates
MarketBeat6 hours ago
Investing.com19 Jul 202412:16 am
Investing.com19 Jul 202412:16 am

Neurocrine Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue0.0%515515499453420412388378311312296289237248259302237244222184138
Cost Of Revenue-----------------2.002.002.00-1.00
Costs and Expenses14.0%416365358379535309300324308348252226205176303226178-132149-
Operating Expenses----------326---176303226178195132149239
  S&GA Expenses11.1%24321920422224318318618320115715514312910711397.0011810185.0081.0088.00
  R&D Expenses-------------73.00---58.00--62.0038.00
EBITDA Margin32.5%0.25*0.19*0.15*0.15*0.07*0.16*0.08*0.04*0.11*0.12*0.18*0.10*0.13*--------
Interest Expenses0%1.001.001.001.001.001.001.002.003.007.007.006.006.008.009.008.008.008.008.008.008.00
Income Taxes-117.6%-8.9051.0033.0026.00-26.7029.0029.00-6.408.00-6.508.0015.00-4.90-3061.004.002.005.005.001.00-0.50
Earnings Before Taxes-82.6%35.00198116122-10311898.00-23.3021.00-13.8031.0058.0027.0042.00-57.1083.0039.0039.0058.0052.00-102
EBT Margin34.7%0.24*0.18*0.14*0.14*0.06*0.14*0.06*0.01*0.08*0.09*0.15*0.07*0.09*--------
Net Income-70.6%43.0014883.0096.00-76.6089.0069.00-16.9014.00-7.3023.0042.0032.00348-57.6080.0037.0034.0054.0051.00-102
Net Income Margin41.0%0.19*0.13*0.11*0.11*0.04*0.10*0.04*0.01*0.06*0.08*0.42*0.35*0.38*--------
Free Cashflow0.8%119118204173-133141101129-48.10-4.7056.0099.0083.00--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets6.8%3,4723,2512,8482,6132,3602,3692,1432,0062,1452,0732,0171,9561,8461,7351,5031,5161,3621,3061,1801,067958
  Current Assets11.9%1,7991,6071,6501,4971,4331,4541,2061,0191,0189731,0061,1101,0851,0161,1571,146968831819749633
    Cash Equivalents57.8%39625129416010427121216327034431136835319042541518711617214778.00
  Inventory-2.9%37.0038.0029.0032.0033.0035.0037.0029.0029.0031.0026.0028.0030.0028.0021.0022.0021.0017.0011.0012.0013.00
  Net PPE6.4%75.0071.0069.0066.0063.0059.0061.0067.0064.0059.0051.0050.0045.0045.0043.0045.0042.0042.0040.0040.0037.00
Liabilities6.6%1,0861,019846760675661599582753699671677641609698684662669605583548
  Current Liabilities8.9%71365569258337453848528625424622621319018761157314056511610172.00
  Long Term Debt-----170--169378335331326322318--414-404398393
    LT Debt, Current-27.8%123170170170-169169-------425420-409---
    LT Debt, Non Current-----170--169378335331326322318--414-404398393
Shareholder's Equity6.9%2,3862,2322,0021,8531,6851,7081,5451,4231,3911,3741,3461,2791,2061,126804831700637575484409
  Retained Earnings27.6%-113-157-304-387-483-406-495-564-547-635-628-651-693-725-1,073-1,015-1,095-1,132-1,166-1,220-1,271
  Additional Paid-In Capital4.8%2,4962,3822,3092,2422,1712,1222,0542,0001,9482,0111,9741,9291,8981,8501,8741,8421,7971,7681,7401,7031,681
Shares Outstanding1.9%10199.0098.0098.0097.0097.0096.0096.0095.0095.0095.0094.00---------
Float----7,900---8,097---9,105---11,232---5,753-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations5.5%130,300123,500212,000179,600-125,200143,00098,800138,100-40,5004,20061,800103,20087,30094,500-20,400118,90035,50097,50097,80064,200-112,500
  Share Based Compensation16.8%44,50038,10047,80068,50039,90043,50043,10049,50037,00035,60037,10028,60032,90021,00026,70029,50022,80021,30020,30017,90015,800
Cashflow From Investing72.7%-55,000-201,800-97,300-125,900-42,100-115,600-61,30031,400-31,60023,700-126,200-90,80063,100-147,70025,20093,40033,200-166,200-85,600-30041,000
Cashflow From Financing97.5%69,90035,40018,8002,9008,20024,60011,400-276,4006,1001,8007,5003,00015,100-185,0005,40015,8006,00012,40013,1004,3002,600
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

NBIX Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:  
Total revenues$ 515.3$ 420.4
Operating expenses:  
Cost of revenues7.58.5
Research and development159.4139.5
Acquired in-process research and development6.0143.9
Selling, general and administrative243.1242.7
Total operating expenses416.0534.6
Operating income (loss)99.3(114.2)
Other (expense) income:  
Interest expense(1.1)(1.1)
Unrealized gain on equity security investments1.62.2
Charges associated with convertible senior notes(88.7)0.0
Investment income and other, net23.49.8
Total other (expense) income, net(64.8)10.9
Income (loss) before benefit from income taxes34.5(103.3)
Benefit from income taxes(8.9)(26.7)
Net income (loss)43.4(76.6)
Foreign currency translation adjustments, net of tax(0.5)1.2
Unrealized (loss) gain on debt securities available-for-sale, net of tax(3.2)4.0
Comprehensive income (loss)$ 39.7$ (71.4)
Earnings (loss) per share:  
Basic (in USD per share)$ 0.43$ (0.79)
Diluted (in USD per share)$ 0.42$ (0.79)
Weighted-average shares outstanding:  
Basic (in shares)99.897.1
Diluted (in shares)103.697.1
Net product sales  
Revenues:  
Total revenues$ 509.0$ 415.3
Collaboration revenues  
Revenues:  
Total revenues$ 6.3$ 5.1

NBIX Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 396.3$ 251.1
Debt securities available-for-sale814.3780.5
Accounts receivable450.7439.3
Inventory37.238.3
Other current assets100.597.8
Total current assets1,799.01,607.0
Deferred tax assets378.2362.6
Debt securities available-for-sale700.4687.5
Right-of-use assets270.8276.5
Equity security investments163.5161.9
Property and equipment, net75.370.8
Intangible assets, net34.335.5
Other noncurrent assets50.949.6
Total assets3,472.43,251.4
Current liabilities:  
Accounts payable and accrued liabilities417.2448.8
Convertible senior notes, at carrying value ($170.4 face value as of March 31, 2024 and December 31, 2023)122.8170.1
Convertible senior notes embedded derivative liability136.20.0
Other current liabilities36.735.9
Total current liabilities712.9654.8
Noncurrent operating lease liabilities252.9258.3
Other noncurrent liabilities120.5106.3
Total liabilities1,086.31,019.4
Stockholders’ equity:  
Preferred stock, $0.001 par value; 5.0 million shares authorized; no shares issued and outstanding0.00.0
Common stock, $0.001 par value; 220.0 shares authorized; 100.6 and 98.7 shares issued and outstanding, respectively0.10.1
Additional paid-in capital2,496.42,382.0
Accumulated other comprehensive income3.37.0
Accumulated deficit(113.7)(157.1)
Total stockholders’ equity2,386.12,232.0
Total liabilities and stockholders’ equity$ 3,472.4$ 3,251.4
NBIX
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
 CEO
 WEBSITEneurocrine.com
 INDUSTRYPharmaceuticals
 EMPLOYEES1350

Neurocrine Biosciences Inc Frequently Asked Questions


What is the ticker symbol for Neurocrine Biosciences Inc? What does NBIX stand for in stocks?

NBIX is the stock ticker symbol of Neurocrine Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Neurocrine Biosciences Inc (NBIX)?

As of Fri Jul 19 2024, market cap of Neurocrine Biosciences Inc is 14.67 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NBIX stock?

You can check NBIX's fair value in chart for subscribers.

What is the fair value of NBIX stock?

You can check NBIX's fair value in chart for subscribers. The fair value of Neurocrine Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Neurocrine Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NBIX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Neurocrine Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether NBIX is over valued or under valued. Whether Neurocrine Biosciences Inc is cheap or expensive depends on the assumptions which impact Neurocrine Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NBIX.

What is Neurocrine Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, NBIX's PE ratio (Price to Earnings) is 39.69 and Price to Sales (PS) ratio is 7.4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NBIX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Neurocrine Biosciences Inc's stock?

In the past 10 years, Neurocrine Biosciences Inc has provided 0.268 (multiply by 100 for percentage) rate of return.